Information for consumers
Sovaldi
® and Harvoni™ are approved for the treatment of chronic Hepatitis C, a viral infection of the liver. Sovaldi
® and Harvoni™ act by preventing the multiplication of hepatitis C virus.
Amiodarone is approved for treating irregular rapid heartbeat and reoccurring heart rhythm problems.
Patients and caregivers should contact their Healthcare Professionals for further evaluation if they are taking amiodarone with either Sovaldi
® or Harvoni™.
Patients who develop the following signs or symptoms of symptomatic bradycardia should seek medical evaluation immediately:
-
Near-fainting or fainting
-
Dizziness or lightheadedness
-
Malaise
-
Weakness
-
Excessive tiredness
-
Shortness of breath
-
Chest pains
-
Confusion or memory problems
Patients should not stop taking their medicines before talking to their healthcare provider.
Information for health care professionals
The co-administration of amiodarone with either Harvoni™ or Sovaldi
® in combination with another DAA is not recommended. Healthcare professionals should counsel patients about the risk of serious symptomatic bradycardia when co administering amiodarone with either Harvoni™ or Sovaldi
® in combination with another DAA.
In cases where concomitant administration of amiodarone and Harvoni™ or Sovaldi
® in combination with another DAA is unavoidable as judged by a medical practitioner, it is recommended that heart monitoring within an in-patient setting be conducted in the first 48 hours followed by daily self-monitoring of the heart rate in the first 2 weeks of treatment.
Due to amiodarone’s long half-life (15 – 142 days, mean 58 days), patients discontinuing amiodarone less than 3 months before starting Harvoni™ or Sovaldi
® in combination with a DAA should also undergo cardiac monitoring as outlined above.
Action taken by Health Canada
Health Canada is working with Gilead Sciences Canada to update the Warnings and Precautions, Post-market Adverse Drug Reactions and Drug Interactions Sections of the Sovaldi
® and Harvoni™ product monographs to reflect this new information.